Lack of comprehensive cost-benefit evaluation for medical products in Panama disadvantages UK exporters
Trade barrier summary
Government purchases of medicines and medical products does not follow a comprehensive cost-benefit evaluation of the product. This makes it difficult for UK companies looking to introduce new and innovative technologies and treatments in the market.
Sectors affected
- Pharmaceuticals and biotechnology
- Healthcare services
Resolved
No
Date reported
23 April 2021
Last updated
26 November 2021
Public ID
PID-9ZOKXB
If a trade barrier is affecting your exports or investment from the UK, please let us know on report a trade barrier .
If you export goods you can check duties and customs procedures for your chosen market.